Publikationen, an denen er mitarbeitet Rafael Rubio García (9)

2020

  1. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 3, pp. 194-195

  2. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: Results of the neurocognitive substudy of the SALT randomized clinical trial

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2444-2451

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2009

  1. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-Week analysis

    Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 2, pp. 147-152

  2. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression

    Antiviral Therapy, Vol. 14, Núm. 2, pp. 195-201

2008

  1. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV

    AIDS, Vol. 22, Núm. 2

  2. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313